Mark Gurnell

University of Cambridge — United Kingdom

Medicine · Health Sciences

56h-index13.4kcitations410works3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pituitary Gland Disorders and Treatments(136), Adrenal and Paraganglionic Tumors(112), Hormonal Regulation and Hypertension(79), Growth Hormone and Insulin-like Growth Factors(66), Adrenal Hormones and Disorders(49)

Publications402 total

P202 On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER
2025
P198 Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study
2025
Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study
The Lancet Diabetes & Endocrinology·2025· 1 citedOpen Access
Voxel-Level Comparison of [ <sup>18</sup> F]CETO and [ <sup>11</sup> C]MTO for Molecular Imaging of Primary Aldosteronism
Journal of Nuclear Medicine Technology·2025
Novel Imaging Modalities in the Evaluation of Patients with Pituitary Adenomas
Endocrinology and Metabolism Clinics of North America·2025
MON-107 A Novel Approach to Corticotroph Adenoma Localization: 11C Methionine PET/CT Following Osilodrostat Therapy
Journal of the Endocrine Society·2025Open Access
Reply to the letter by Dr Karlsson ‘Rationale behind the European Thyroid Association 2024 Guideline to treat the Allan–Herndon–Dudley syndrome with tiratricol?’
European Thyroid Journal·2025Open Access
OCS reduction with tezepelumab in OCS-dependent patients with severe allergic, eosinophilic asthma in WAYFINDER
2025
On-treatment clinical remission with tezepelumab in OCS-dependent patients with severe asthma in WAYFINDER
2025
Enhanced Radiological Detection of a Corticotroph Adenoma Following Treatment With Osilodrostat
JCEM Case Reports·2025· 1 citedOpen Access
Is It Time to Retire Aldosterone Suppression Testing?
American Journal of Hypertension·2025· 4 citedOpen Access
Consensus on acromegaly therapeutic outcomes: an update
Nature Reviews Endocrinology·2025· 19 citedOpen Access
A core outcome set for pituitary surgery research: an international delphi consensus study
Pituitary·2025· 4 citedOpen Access
Pituitary incidentaloma: a Pituitary Society international consensus guideline statement
Nature Reviews Endocrinology·2025· 16 citedOpen Access
Disrupted ACTH and cortisol response to osmotic and non-osmotic stress in patients with arginine vasopressin deficiency
European Journal of Endocrinology·2025· 3 citedOpen Access
Molecular imaging is non-inferior to adrenal vein sampling for diagnosing surgically curable primary aldosteronism: a prospective, within-patient study
Efficacy and Mechanism Evaluation·2025Open Access
Real-world experience with 68Ga-Pentixa for positron emission tomography in the management of primary aldosteronism
Endocrine Abstracts·2025
Improving tumour localisation in cushing's disease: synergistic use of 11c-methionine pet/ct and osilodrostat
Endocrine Abstracts·2025
Evaluation of the overnight dexamethasone suppression test in a large cohort of patients with incidentally discovered adrenal nodules
Endocrine Abstracts·2025
A comparative analysis of three positron emission tomography tracers in a patient with residual acromegaly
Endocrine Abstracts·2025
page 1 of 21Next →

Frequent Co-authors

Krishna Chatterjee(15), Maura Agostini(11), Maria Fleseriu(8), David Halsall(8), Stephen O’Rahilly(7), John Wass(7), Odelia Rajanayagam(7), Andrew Powlson(7), John W. R. Schwabe(6), Michael Buchfelder(6), Mônica R. Gadelha(6), Ann McCormack(6), Stephan Petersenn(6), David B. Savage(5), Nienke R. Biermasz(5), Felipe F. Casanueva(5), Philippe Chanson(5), Andrea Giustina(5), Ken K. Y. Ho(5), Adriana G. Ioachimescu(5)